Angiotensin Receptor and Neprilysin Inhibitors for COVID-19 Treatment and Personalized Medicine?

Matsumura T , Kugiyama K , Sugiyama S , et al. (1996). Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity. J Clin Invest, 97, 2192–2203.

McMurray JJ , Packer M , Desai AS , et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 371, 993–1004.

O'Donnell C , Ashland MD , Vasti EC , et al. (2021). N-terminal Pro-B-Type natriuretic peptide as a biomarker for the severity and outcomes with COVID-19 in a Nationwide Hospitalized Cohort. J Am Heart Assoc, 10, e022913.

Rex DAB , Arun Kumar ST , Modi PK , Keshava Prasad TS . (2021). Broadening COVID-19 interventions to drug innovation: Neprilysin pathway as a friend, foe, or promising molecular target?. OMICS, 25, 408–416.

Zhang Q , Zhang H , Yan X , et al. (2021). Neutrophil infiltration induces myocardial injury in COVID-19 post-mortem cases. Preprint. SSRN ssrn.3969814. [Epub ahead of print]; DOI: 10.2139/ssrn.3969814.